New therapeutic targets for cancer bone metastasis

Trends in Pharmacological Sciences

Volumn 36, Issue 6, 2015, Pages 360-373

  Krzeszinski, Jing Y ^a   Wan, Yihong ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bone metastatic niche; Bone microenvironment; Macrometastasis; Osteoblast; Osteoclast; Tumor intrinsic factors

Indexed keywords

AFLIBERCEPT; ATRASENTAN; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CABOZANTINIB; CEDIRANIB; DASATINIB; DENOSUMAB; DOVITINIB; FRESOLIMUMAB; GALUNISERTIB; MICRORNA 126; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NINTEDANIB; PLERIXAFOR; SARACATINIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT;

ADIPOCYTE; ARTICLE; BONE CELL; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CELL HYPOXIA; CELLULAR SECRETION; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE; MICROMETASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; STEM CELL NICHE; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; BONE NEOPLASMS; CANCER STEM CELL; DRUG EFFECTS; METABOLISM; PATHOLOGY; SECONDARY; TUMOR EMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84934923163     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.04.006     Document Type: Review

References (166)

1. Randall, R.L. (2014) A promise to our patients with metastatic bone disease. Ann. Surg. Oncol. 21, 4049-4050
2. Davila, D. et al. (2015) Evaluation of osseous metastasis in bone scintigraphy. Semin. Nucl. Med. 45, 3-15
3. Quinn, R.H. et al. (2014) Contemporary management of metastatic bone disease: tips and tools of the trade for general practitioners. Instr. Course Lect. 63, 431-441
4. Taubenberger, A.V. (2014) In vitro microenvironments to study breast cancer bone colonisation. Adv. Drug Deliv. Rev. 79-80C, 135-144
5. Jandial, R. (2013) Metastatic Cancer: Clinical and Biological Perspectives, CRC Press
6. Leber, M.F. and Efferth, T. (2009) Molecular principles of cancer invasion and metastasis. Int. J. Oncol. 34, 881-895
7. Lamouille, S. et al. (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178-196
8. van Roy, F. and Berx, G. (2008) The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65, 3756-3788
9. Peifer, M. et al. (1992) The vertebrate adhesive junction proteins betacatenin and plakoglobin and the Drosophila segment polarity gene armadillo form a multigene family with similar properties. J. Cell Biol. 118, 681-691
10. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687
11. Sethi, S. et al. (2010) Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res. 3, 90-99
12. Smith, B.A. et al. (2014) Abstract C60: Snail transcription factor contributes to bone metastasis in prostate and breast cancer cells. Cancer Epidemiol. Biomark. Prev. 23, C60
13. Croset, M. et al. (2014) TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J. Bone Miner. Res. 29, 1886-1899
14. Semenza, G.L. (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634
15. Vaupel, P. (2009) Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv. Exp. Med. Biol. 645, 241-246
16. Mathieu, J. et al. (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71, 4640-4652
17. Jing, S-W. et al. (2013) Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation. Dis. Esophagus 26, 75-83
18. Yang, M-H. et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 10, 295-305
19. Stoeltzing, O. et al. (2003) Regulation of hypoxia-inducible factor- 1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 163, 1001-1011
20. Lu, X. and Kang, Y. (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res. 16, 5928-5935
21. Chen, J. et al. (2010) Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br. J. Cancer 102, 351-360
22. Lundgren, K. et al. (2009) Hypoxia, Snail and incomplete epithelialmesenchymal transition in breast cancer. Br. J. Cancer 101, 1769-1781
23. Xing, F. et al. (2011) Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 30, 4075-4086
24. Dunn, L.K. et al. (2009) Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 4, e6896
25. Mishra, A. et al. (2012) Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol. Cancer Res. 10, 703-712
26. Harada, R. et al. (2013) Reoxygenation using a novel CO2 therapy decreases the metastatic potential of osteosarcoma cells. Exp. Cell Res. 319, 1988-1997
27. Gilkes, D.M. et al. (2014) Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430-439
28. Eckhardt, B.L. et al. (2005) Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol. Cancer Res. 3, 1-13
29. Hubmacher, D. and Apte, S.S. (2013) The biology of the extracellular matrix: novel insights. Curr. Opin. Rheumatol. 25, 65-70
30. Coussens, L.M. et al. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392
31. Wang, H. et al. (2013) miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin b1 and matrix metalloproteinase2 (MMP2). PLoS ONE 8, e70192
32. Papetti, M. and Herman, I.M. (2002) Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947-C970
33. Dimova, I. et al. (2014) Angiogenesis in cancer - general pathways and their therapeutic implications. J. BUON 19, 15-21
34. Couzin-Frankel, J. and Ogale, Y. (2011) FDA. Once on 'fast track'; avastin now derailed. Science 333, 143-144
35. Fay, A.P. et al. (2015) Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 15, 151-156
36. Schweizer, M.T. and Carducci, M.A. (2013) From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J. 19, 99-106
37. Petrillo, M. et al. (2012) Novel targets for VEGF-independent antiangiogenic drugs. Expert Opin. Investig. Drugs 21, 451-472
38. Chu, Q.S-C. (2009) Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin. Biol. Ther. 9, 263-271
39. Weis, S.M. and Cheresh, D.A. (2011) aV integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 1, a006478
40. Martinez, L.M. et al. (2014) Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases. Clin. Exp. Metastasis 31, 213-232
41. Kang, Y. et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549
42. Conti, A. et al. (2014) Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. Clin. Exp. Metastasis 31, 15-24
43. Sieh, S. et al. (2014) Paracrine interactions between LNCaP prostate cancer cells and bioengineered bone in 3D in vitro culture reflect molecular changes during bone metastasis. Bone 63, 121-131
44. Wang, H. et al. (2013) Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer. Mol. Clin. Oncol. 1, 1031-1038
45. Welch, D.R. (2004) Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res. 6, 61-64
46. Palumbo, J.S. et al. (2007) Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 110, 133-141
47. Coupland, L.A. et al. (2012) Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 72, 4662-4671
48. Schumacher, D. et al. (2013) Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 24, 130-137
49. Labelle, M. et al. (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20, 576-590
50. Okamoto, T. et al. (2013) Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity. Mol. Med. Rep. 7, 359-364
51. Giuliano, M. et al. (2014) Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 16, 440
52. Giuliano, M. et al. (2015) Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 17, 3
53. Mumford, B.S. and Robertson, G.P. (2014) Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol. Diagn. Ther. 18, 175-183
54. Hirbe, A.C. et al. (2010) The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr. Pharm. Des. 16, 1284-1290
55. Richert, M.M. et al. (2009) Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol. Rep. 21, 761-767
56. Smith, M.C.P. et al. (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64, 8604-8612
57. Hirbe, A.C. et al. (2007) Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc. Natl. Acad. Sci. U.S.A. 104, 14062-14067
58. Lapidot, T. and Kollet, O. (2002) The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16, 1992-2003
59. Burns, J.M. et al. (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201-2213
60. Azab, A.K. et al. (2014) CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood 124, 1905-1914
61. Lee, J-H. et al. (2012) CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Cancer Res. 72, 3175-3186
62. Yin, J.J. et al. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206
63. Kang, Y. et al. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U.S.A. 102, 13909-13914
64. Bendre, M.S. et al. (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res. 62, 5571-5579
65. Siclari, V.A. et al. (2014) Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis. Breast Cancer Res. 16, 1693
66. Png, K.J. et al. (2012) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481, 190-194
67. Tavazoie, S.F. et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152
68. Liu, Q. et al. (2013) Interleukin-1b promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Res. 73, 3297-3305
69. Lee, Y-C. et al. (2015) Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol. Cell Proteomics 14, 471-483
70. Valencia, K. et al. (2012) Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin. Cancer Res. 18, 969-980
71. Antón, I. et al. (2012) Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 186, 96-105
72. Luis-Ravelo, D. et al. (2014) A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer. Oncogene 33, 5090-5099
73. Nguyen, D.X. et al. (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62
74. Gong, M. et al. (2014) miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol. Cancer Res. 12, 101-110
75. Peinado, H. et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891
76. Schofield, R. (1978) The relationship between the spleen colonyforming cell and the haemopoietic stem cell. Blood Cells 4, 7-25
77. Kiel, M.J. et al. (2005) SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 121, 1109-1121
78. Xie, Y. et al. (2009) Detection of functional haematopoietic stem cell niche using real-time imaging. Nature 457, 97-101
79. Müller, A. et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56
80. Taichman, R.S. et al. (2002) Use of the stromal cell-derived factor-1/ CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62, 1832-1837
81. Shiozawa, Y. et al. (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 121, 1298-1312
82. Calvi, L.M. et al. (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846
83. Kim, J.K. et al. (2013) TBK1 regulates prostate cancer dormancy through mTOR inhibition. NEO 15, 1064-1074
84. Shiozawa, Y. et al. (2010) GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. NEO 12, 116-127
85. Shiozawa, Y. et al. (2010) GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp. Hematol. 38, 132-140
86. Jung, Y. et al. (2008) Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells 26, 2042-2051
87. Joseph, J. et al. (2012) Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol. Cancer Res. 10, 282-292
88. Grassinger, J. et al. (2007) Bone morphogenetic protein (BMP)-7 but not BMP-2 and BMP-4 improves maintenance of primitive peripheral blood-derived hematopoietic progenitor cells (HPC) cultured in serum-free medium supplemented with early acting cytokines. Cytokine 40, 165-171
89. Kobayashi, A. et al. (2011) Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 208, 2641-2655
90. Johnson, R.W. et al. (2011) TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 71, 822-831
91. Bandyopadhyay, A. et al. (2006) Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 66, 6714-6721
92. Mohammad, K.S. et al. (2011) TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 71, 175-184
93. Li, X. et al. (2012) Loss of TGF-b responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol. Cancer Res. 10, 494-503
94. Yakar, S. et al. (2010) IGF-1 and bone: New discoveries from mouse models. J. Bone Miner. Res. 25, 2543-2552
95. Hiraga, T. et al. (2012) Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res. 72, 4238-4249
96. Corn, P.G. et al. (2013) Targeting fibroblast growth factor pathways in prostate cancer. Clin. Cancer Res. 19, 5856-5866
97. Motzer, R.J. et al. (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 15, 286-296
98. Wan, X. et al. (2014) Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci. Transl. Med. 6, 252ra122
99. Catena, R. et al. (2011) PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res. 71, 164-174
100. Bai, H. et al. (2014) CCL5 secreted from bone marrow stromal cells stimulates the migration and invasion of Huh7 hepatocellular carcinoma cells via the PI3K-Akt pathway. Int. J. Oncol. 45, 333-343
101. Felding-Habermann, B. et al. (2001) Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 98, 1853-1858
102. Sloan, E.K. et al. (2006) Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8, R20
103. Zhao, Y. et al. (2007) Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 67, 5821-5830
104. 2), a beta integrin antagonist, in patients with solid tumours. Br. J. Cancer 94, 1621-1626
105. Khalili, P. et al. (2006) A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5, 2271-2280
106. Kawaguchi, J. et al. (2001) Targeted disruption of cadherin-11 leads to a reduction in bone density in calvaria and long bone metaphyses. J. Bone Miner. Res. 16, 1265-1271
107. Huang, C-F. et al. (2010) Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 70, 4580-4589
108. Chu, K. et al. (2008) Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol. Cancer Res. 6, 1259-1267
109. Tamura, D. et al. (2008) Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int. J. Oncol. 33, 17-24
110. Wang, H. et al. (2015) The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell 27, 193-210
111. Ferrari-Amorotti, G. et al. (2014) Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. NEO 16, 1047-1058
112. Glavey, S.V. et al. (2014) The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood 124, 1765-1776
113. Hedges, E.A. et al. (2014) Modulation of selectin-mediated adhesion of flowing lymphoma and bone marrow cells by immobilized SDF-1. Int. J. Mol. Sci. 15, 15061-15072
114. Hiraga, T. et al. (2013) Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 73, 4112-4122
115. Guise, T.A. (2002) The vicious cycle of bone metastases. J. Musculoskelet. Neuronal Interact. 2, 570-572
116. Li, B. et al. (2014) Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice. J. Clin. Med. 3, 1-24
117. Misso, G. et al. (2012) Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol. Ther. 13, 1491-1500
118. Santini, D. et al. (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8, 1080-1084
119. Santini, D. et al. (2003) Zoledronic acid induces significant and longlasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9, 2893-2897
120. Santini, D. et al. (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13, 4482-4486
121. Vincenzi, B. et al. (2003) Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann. Oncol. 14, 806-807
122. Wu, S. et al. (2007) The use of bisphosphonates in cancer patients. Acta Oncol. 46, 581-591
123. Drooger, J.C. et al. (2013) Denosumab in breast cancer treatment. Eur. J. Pharmacol. 717, 12-19
124. Massagué, J. (2008) TGFbeta in Cancer. Cell 134, 215-230
125. Buijs, J.T. et al. (2011) TGF-b in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron. 4, 261-281
126. Connolly, E.C. et al. (2012) Complexities of TGF-b targeted cancer therapy. Int. J. Biol. Sci. 8, 964-978
127. Koreckij, T. et al. (2009) Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br. J. Cancer 101, 263-268
128. Saad, F. and Lipton, A. (2010) SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat. Rev. 36, 177-184
129. Marzia, M. et al. (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell Biol. 151, 311-320
130. Gucalp, A. et al. (2011) Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptornegative metastatic breast cancer. Clin. Breast Cancer 11, 306-311
131. Hannon, R.A. et al. (2010) Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J. Bone Miner. Res. 25, 463-471
132. Brown, J.E. and Coleman, R.E. (2012) Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat. Rev. Clin. Oncol. 9, 110-118
133. Coleman, R.E. (2012) Bone cancer in 2011: prevention and treatment of bone metastases. Nat. Rev. Clin. Oncol. 9, 76-78
134. Khosla, S. et al. (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 22, 1479-1491
135. Ell, B. et al. (2013) Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24, 542-556
136. Krzeszinski, J.Y. et al. (2014) miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature 512, 431-435
137. Hermeking, H. (2007) p53 enters the microRNA world. Cancer Cell 12, 414-418
138. Liu, C. et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17, 211-215
139. Valencia, K. et al. (2014) miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol. Oncol. 8, 689-703
140. Guise, T.A. (2009) Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev. 23, 2117-2123
141. Jones, M.D. et al. (2010) A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin. Cancer Res. 16, 4978-4989
142. Richardson, P.G. et al. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498
143. Clines, G.A. et al. (2007) Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol. Endocrinol. 21, 486-498
144. Carducci, M.A. and Jimeno, A. (2006) Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin. Cancer Res. 12, 6296s-6300s
145. Chiao, J.W. et al. (2000) Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br. J. Cancer 83, 360-365
146. Pinto, A. et al. (2012) Targeting the endothelin axis in prostate carcinoma. Tumour Biol. 33, 421-426
147. Hardaway, A.L. et al. (2014) Bone marrow fat: linking adipocyteinduced inflammation with skeletal metastases. Cancer Metastasis Rev. 33, 527-543
148. Gazi, E. et al. (2007) Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J. Lipid Res. 48, 1846-1856
149. Tokuda, Y. et al. (2003) Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int. 91, 716-720
150. Furuhashi, M. and Hotamisligil, G.S. (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7, 489-503
151. Herroon, M.K. et al. (2013) Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 4, 2108-2123
152. Herroon, M.K. et al. (2013) Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene 32, 1580-1593
153. Lawrence, T. and Natoli, G. (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat. Rev. Immunol. 11, 750-761
154. Zhang, M. et al. (2014) A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J. Ovarian Res. 7, 19
155. Joshi, S. et al. (2014) Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS ONE 9, e95893
156. Hiraoka, K. et al. (2008) Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/ macrophages. Cancer Sci. 99, 1595-1602
157. Fend, L. et al. (2013) Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS ONE 8, e73310
158. Okuda, H. et al. (2012) Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res. 72, 537-547
159. Lelekakis, M. et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17, 163-170
160. Uluckan, O. et al. (2008) APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J. Cell. Biochem. 104, 1311-1323
161. Chaffer, C.L. et al. (2005) Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. Clin. Exp. Metastasis 22, 115-125
162. Yang, M. et al. (1998) Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Cancer Res. 58, 4217-4221
163. Yang, M. et al. (1999) A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 59, 781-786
164. Yang, M. et al. (1999) Genetically fluorescent melanoma bone and organ metastasis models. Clin. Cancer Res. 5, 3549-3559
165. Miwa, S. et al. (2014) Tumor-targeting Salmonella typhimurium A1-R prevents experimental human breast cancer bone metastasis in nude mice. Oncotarget 5, 7119-7125
166. Miwa, S. et al. (2014) Fluorescence-guided surgery of prostate cancer bone metastasis. J. Surg. Res. 192, 124-133